Anti-amyloid antibodies slow decline in early Alzheimer (lecanemab -27% over 18 months; donanemab about one third), with brain swelling and microbleeds (ARIA); approved.
Confidence
Established
Level of evidence
●●●●●● Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisAnti-amyloid antibodies (lecanemab, donanemab)Alzheimer's disease
What the sources say
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).